| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 43 | 2025 | 529 | 4.930 |
Why?
|
| Streptococcal Infections | 31 | 2021 | 184 | 4.170 |
Why?
|
| Streptococcus agalactiae | 34 | 2021 | 202 | 3.840 |
Why?
|
| Influenza Vaccines | 19 | 2025 | 144 | 3.370 |
Why?
|
| Vaccination | 33 | 2025 | 365 | 3.350 |
Why?
|
| Vaccines | 12 | 2024 | 86 | 2.750 |
Why?
|
| Pregnancy | 70 | 2025 | 1862 | 2.490 |
Why?
|
| Influenza, Human | 18 | 2025 | 374 | 2.250 |
Why?
|
| Humans | 140 | 2025 | 14537 | 2.080 |
Why?
|
| Female | 108 | 2025 | 9103 | 2.030 |
Why?
|
| Pneumococcal Vaccines | 17 | 2025 | 278 | 1.960 |
Why?
|
| Infant, Newborn | 48 | 2024 | 1479 | 1.870 |
Why?
|
| Infant | 65 | 2025 | 2244 | 1.790 |
Why?
|
| Immunization | 12 | 2023 | 63 | 1.700 |
Why?
|
| Meningococcal Vaccines | 3 | 2023 | 12 | 1.580 |
Why?
|
| Antibodies, Bacterial | 20 | 2025 | 153 | 1.570 |
Why?
|
| HIV Infections | 38 | 2023 | 5097 | 1.570 |
Why?
|
| Immunoglobulin G | 16 | 2025 | 231 | 1.540 |
Why?
|
| Immunization Schedule | 16 | 2025 | 81 | 1.520 |
Why?
|
| Antibodies, Viral | 22 | 2023 | 284 | 1.500 |
Why?
|
| Stillbirth | 8 | 2024 | 83 | 1.440 |
Why?
|
| Pneumococcal Infections | 14 | 2025 | 299 | 1.410 |
Why?
|
| Streptococcus pneumoniae | 10 | 2025 | 336 | 1.360 |
Why?
|
| Immunogenicity, Vaccine | 11 | 2025 | 103 | 1.330 |
Why?
|
| Tetanus Toxoid | 3 | 2025 | 14 | 1.270 |
Why?
|
| Data Collection | 8 | 2019 | 86 | 1.220 |
Why?
|
| South Africa | 58 | 2025 | 7596 | 1.210 |
Why?
|
| Vagina | 7 | 2017 | 91 | 1.120 |
Why?
|
| Bacterial Infections | 5 | 2019 | 54 | 1.010 |
Why?
|
| Maternal Death | 2 | 2024 | 25 | 1.010 |
Why?
|
| Adult | 44 | 2025 | 5913 | 0.990 |
Why?
|
| Infectious Disease Transmission, Vertical | 6 | 2019 | 472 | 0.990 |
Why?
|
| Meningococcal Infections | 2 | 2023 | 24 | 0.980 |
Why?
|
| Infant, Newborn, Diseases | 8 | 2020 | 73 | 0.960 |
Why?
|
| Young Adult | 27 | 2025 | 2498 | 0.900 |
Why?
|
| Vaccines, Conjugate | 16 | 2025 | 171 | 0.900 |
Why?
|
| Pneumonia | 6 | 2023 | 131 | 0.870 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 38 | 0.850 |
Why?
|
| Women's Health | 1 | 2023 | 41 | 0.840 |
Why?
|
| Reproductive Health | 1 | 2023 | 51 | 0.830 |
Why?
|
| Neisseria meningitidis | 1 | 2023 | 36 | 0.800 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2017 | 8 | 0.800 |
Why?
|
| Male | 42 | 2025 | 6754 | 0.770 |
Why?
|
| Respiratory Syncytial Virus, Human | 7 | 2022 | 155 | 0.760 |
Why?
|
| Serogroup | 8 | 2025 | 150 | 0.750 |
Why?
|
| Epidemiologic Methods | 2 | 2017 | 25 | 0.730 |
Why?
|
| Respiratory Syncytial Virus Infections | 6 | 2022 | 200 | 0.710 |
Why?
|
| Immunity, Maternally-Acquired | 5 | 2019 | 40 | 0.680 |
Why?
|
| Sepsis | 4 | 2016 | 102 | 0.660 |
Why?
|
| Immunization, Secondary | 7 | 2025 | 72 | 0.650 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 39 | 0.650 |
Why?
|
| Clinical Trials as Topic | 6 | 2021 | 112 | 0.640 |
Why?
|
| Cause of Death | 2 | 2019 | 221 | 0.620 |
Why?
|
| Streptococcal Vaccines | 8 | 2017 | 47 | 0.610 |
Why?
|
| Infant, Low Birth Weight | 2 | 2017 | 35 | 0.600 |
Why?
|
| Developing Countries | 6 | 2019 | 400 | 0.600 |
Why?
|
| Carrier State | 6 | 2020 | 92 | 0.590 |
Why?
|
| Antibodies, Neutralizing | 7 | 2023 | 303 | 0.590 |
Why?
|
| Incidence | 15 | 2021 | 685 | 0.580 |
Why?
|
| Child, Preschool | 22 | 2023 | 1748 | 0.550 |
Why?
|
| Prospective Studies | 11 | 2020 | 1160 | 0.530 |
Why?
|
| Adolescent | 15 | 2025 | 2985 | 0.520 |
Why?
|
| Child | 18 | 2024 | 2242 | 0.510 |
Why?
|
| Retrospective Studies | 3 | 2025 | 799 | 0.500 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 5 | 2020 | 54 | 0.490 |
Why?
|
| Double-Blind Method | 16 | 2021 | 272 | 0.480 |
Why?
|
| Coinfection | 3 | 2021 | 276 | 0.470 |
Why?
|
| Rectum | 5 | 2017 | 22 | 0.430 |
Why?
|
| Whooping Cough | 4 | 2024 | 36 | 0.420 |
Why?
|
| Respiratory Tract Infections | 4 | 2020 | 266 | 0.400 |
Why?
|
| Prenatal Care | 3 | 2025 | 147 | 0.400 |
Why?
|
| Nasopharynx | 8 | 2020 | 151 | 0.400 |
Why?
|
| Haemophilus Vaccines | 5 | 2017 | 41 | 0.380 |
Why?
|
| Risk Factors | 15 | 2019 | 1475 | 0.380 |
Why?
|
| Premature Birth | 3 | 2017 | 80 | 0.380 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2022 | 14 | 0.370 |
Why?
|
| Vitamin D Deficiency | 2 | 2022 | 27 | 0.370 |
Why?
|
| Prevalence | 10 | 2024 | 1192 | 0.370 |
Why?
|
| Infant Mortality | 4 | 2020 | 97 | 0.350 |
Why?
|
| Pregnancy Outcome | 6 | 2020 | 117 | 0.340 |
Why?
|
| Chlorhexidine | 1 | 2009 | 10 | 0.330 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.330 |
Why?
|
| Skin | 1 | 2009 | 38 | 0.330 |
Why?
|
| Tetanus | 2 | 2025 | 10 | 0.330 |
Why?
|
| Labor, Obstetric | 1 | 2009 | 44 | 0.330 |
Why?
|
| Measles | 2 | 2019 | 36 | 0.320 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2021 | 195 | 0.320 |
Why?
|
| Cost of Illness | 3 | 2024 | 167 | 0.310 |
Why?
|
| Hemagglutination Inhibition Tests | 6 | 2020 | 23 | 0.300 |
Why?
|
| Gestational Age | 5 | 2020 | 80 | 0.300 |
Why?
|
| Bordetella pertussis | 2 | 2018 | 29 | 0.280 |
Why?
|
| Haemophilus influenzae | 3 | 2020 | 42 | 0.280 |
Why?
|
| Pneumonia, Pneumococcal | 5 | 2021 | 100 | 0.270 |
Why?
|
| Pregnant Women | 7 | 2020 | 89 | 0.270 |
Why?
|
| Case-Control Studies | 5 | 2021 | 480 | 0.260 |
Why?
|
| Global Health | 8 | 2017 | 193 | 0.260 |
Why?
|
| Bacterial Proteins | 3 | 2017 | 119 | 0.260 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2016 | 35 | 0.260 |
Why?
|
| Hepatitis B Vaccines | 4 | 2024 | 40 | 0.260 |
Why?
|
| Vaccination Coverage | 1 | 2025 | 13 | 0.240 |
Why?
|
| Measles Vaccine | 3 | 2019 | 34 | 0.240 |
Why?
|
| Lassa Fever | 1 | 2024 | 2 | 0.240 |
Why?
|
| Lassa virus | 1 | 2024 | 2 | 0.240 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2017 | 28 | 0.240 |
Why?
|
| Hospitalization | 7 | 2021 | 418 | 0.230 |
Why?
|
| Vaccines, Inactivated | 7 | 2018 | 23 | 0.230 |
Why?
|
| HLA-DRB1 Chains | 1 | 2024 | 17 | 0.230 |
Why?
|
| Treatment Outcome | 9 | 2020 | 889 | 0.220 |
Why?
|
| Cross Infection | 1 | 2004 | 52 | 0.220 |
Why?
|
| Vaccines, Combined | 4 | 2017 | 34 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 104 | 0.220 |
Why?
|
| Women's Rights | 1 | 2023 | 4 | 0.220 |
Why?
|
| Reproduction | 1 | 2023 | 25 | 0.210 |
Why?
|
| Cohort Studies | 8 | 2021 | 967 | 0.210 |
Why?
|
| Algorithms | 2 | 2022 | 106 | 0.200 |
Why?
|
| Infant, Premature | 4 | 2016 | 56 | 0.200 |
Why?
|
| Bacteria | 2 | 2015 | 47 | 0.200 |
Why?
|
| Infant Health | 2 | 2021 | 16 | 0.200 |
Why?
|
| Malnutrition | 1 | 2023 | 56 | 0.200 |
Why?
|
| Maternal Health | 2 | 2021 | 20 | 0.200 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2020 | 31 | 0.200 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2020 | 42 | 0.200 |
Why?
|
| HIV-1 | 4 | 2018 | 1260 | 0.190 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 3 | 0.190 |
Why?
|
| Malaria | 2 | 2021 | 213 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 39 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2017 | 21 | 0.180 |
Why?
|
| Bacterial Capsules | 3 | 2015 | 33 | 0.180 |
Why?
|
| Age Factors | 4 | 2019 | 370 | 0.180 |
Why?
|
| Serotyping | 3 | 2017 | 66 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2020 | 150 | 0.180 |
Why?
|
| Mothers | 3 | 2017 | 195 | 0.180 |
Why?
|
| Brain Diseases | 2 | 2017 | 24 | 0.180 |
Why?
|
| Antibody Formation | 5 | 2024 | 61 | 0.180 |
Why?
|
| Obstetrics | 1 | 2020 | 10 | 0.170 |
Why?
|
| Perinatal Death | 2 | 2019 | 33 | 0.170 |
Why?
|
| Africa | 6 | 2021 | 376 | 0.170 |
Why?
|
| Immunity, Humoral | 2 | 2022 | 42 | 0.170 |
Why?
|
| Rubella | 1 | 2019 | 5 | 0.170 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.170 |
Why?
|
| Maternal Mortality | 1 | 2020 | 58 | 0.170 |
Why?
|
| Chorioamnionitis | 1 | 2019 | 10 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 21 | 0.170 |
Why?
|
| Virus Diseases | 2 | 2015 | 55 | 0.170 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 3 | 0.170 |
Why?
|
| Software | 1 | 2019 | 37 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 48 | 0.170 |
Why?
|
| Maternal Exposure | 1 | 2019 | 14 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 23 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 71 | 0.160 |
Why?
|
| Population Surveillance | 3 | 2016 | 325 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2019 | 65 | 0.160 |
Why?
|
| Gambia | 1 | 2019 | 13 | 0.160 |
Why?
|
| Placenta Diseases | 1 | 2019 | 5 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 7 | 0.160 |
Why?
|
| Anemia | 1 | 2019 | 41 | 0.160 |
Why?
|
| Child Development | 1 | 2020 | 93 | 0.160 |
Why?
|
| Neonatal Sepsis | 1 | 2019 | 29 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.160 |
Why?
|
| Influenza B virus | 3 | 2018 | 42 | 0.150 |
Why?
|
| Autopsy | 1 | 2019 | 140 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 244 | 0.150 |
Why?
|
| Risk | 2 | 2015 | 87 | 0.150 |
Why?
|
| Microcephaly | 1 | 2017 | 1 | 0.150 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2017 | 5 | 0.150 |
Why?
|
| Immunization Programs | 1 | 2018 | 81 | 0.150 |
Why?
|
| Middle Aged | 7 | 2021 | 3601 | 0.150 |
Why?
|
| Postpartum Period | 1 | 2018 | 85 | 0.140 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 22 | 0.140 |
Why?
|
| Measles virus | 1 | 2017 | 6 | 0.140 |
Why?
|
| Fimbriae, Bacterial | 2 | 2015 | 10 | 0.130 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 18 | 0.130 |
Why?
|
| Paramyxoviridae Infections | 2 | 2007 | 27 | 0.130 |
Why?
|
| Statistics as Topic | 4 | 2016 | 31 | 0.130 |
Why?
|
| Bacterial Adhesion | 1 | 2016 | 6 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 25 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 45 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.130 |
Why?
|
| Otitis Media | 1 | 2015 | 6 | 0.120 |
Why?
|
| Communicable Disease Control | 1 | 2016 | 101 | 0.120 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2013 | 17 | 0.120 |
Why?
|
| Viral Vaccines | 2 | 2024 | 24 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 14 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2015 | 42 | 0.120 |
Why?
|
| Viruses | 1 | 2015 | 47 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 2 | 0.120 |
Why?
|
| Polyomavirus | 1 | 2014 | 3 | 0.120 |
Why?
|
| Seroepidemiologic Studies | 3 | 2019 | 109 | 0.120 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 43 | 0.110 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2011 | 11 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 104 | 0.110 |
Why?
|
| Hypertension | 1 | 2019 | 419 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 198 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2023 | 225 | 0.110 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Chickenpox Vaccine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 435 | 0.110 |
Why?
|
| Culture Media | 1 | 2013 | 15 | 0.110 |
Why?
|
| Placenta | 3 | 2019 | 44 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2012 | 30 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 370 | 0.100 |
Why?
|
| World Health Organization | 2 | 2023 | 137 | 0.100 |
Why?
|
| Income | 2 | 2023 | 85 | 0.100 |
Why?
|
| Seasons | 3 | 2021 | 154 | 0.100 |
Why?
|
| Klebsiella pneumoniae | 1 | 2012 | 39 | 0.100 |
Why?
|
| Aged | 3 | 2022 | 1740 | 0.100 |
Why?
|
| Colony Count, Microbial | 1 | 2011 | 14 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 65 | 0.100 |
Why?
|
| Pertussis Vaccine | 2 | 2024 | 16 | 0.090 |
Why?
|
| Poverty | 3 | 2016 | 152 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 90 | 0.090 |
Why?
|
| Vitamin D | 2 | 2022 | 41 | 0.090 |
Why?
|
| Poliovirus Vaccines | 1 | 2011 | 11 | 0.090 |
Why?
|
| Iron | 2 | 2022 | 32 | 0.090 |
Why?
|
| Diphtheria | 1 | 2011 | 16 | 0.090 |
Why?
|
| Time Factors | 3 | 2020 | 507 | 0.090 |
Why?
|
| Mali | 2 | 2020 | 20 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 265 | 0.090 |
Why?
|
| Internationality | 2 | 2021 | 36 | 0.080 |
Why?
|
| Infant Care | 1 | 2009 | 10 | 0.080 |
Why?
|
| Metapneumovirus | 2 | 2007 | 30 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2011 | 125 | 0.080 |
Why?
|
| Haemophilus Infections | 2 | 2007 | 23 | 0.080 |
Why?
|
| HIV | 2 | 2015 | 380 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2020 | 17 | 0.080 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2020 | 13 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1422 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 77 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 34 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2020 | 30 | 0.070 |
Why?
|
| Biomarkers | 2 | 2022 | 327 | 0.070 |
Why?
|
| Bacteremia | 2 | 2019 | 79 | 0.070 |
Why?
|
| Meningitis, Bacterial | 2 | 2017 | 38 | 0.070 |
Why?
|
| Developed Countries | 2 | 2017 | 24 | 0.070 |
Why?
|
| Morbidity | 2 | 2016 | 37 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2018 | 260 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2016 | 40 | 0.070 |
Why?
|
| Interferons | 1 | 2006 | 9 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 2006 | 19 | 0.060 |
Why?
|
| Respirovirus Infections | 1 | 2005 | 3 | 0.060 |
Why?
|
| Virulence | 1 | 2006 | 25 | 0.060 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2005 | 5 | 0.060 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2006 | 15 | 0.060 |
Why?
|
| Haemophilus influenzae type b | 1 | 2005 | 17 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 96 | 0.060 |
Why?
|
| Africa, Western | 1 | 2024 | 8 | 0.060 |
Why?
|
| Latex Fixation Tests | 2 | 2015 | 8 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 7 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 181 | 0.060 |
Why?
|
| Length of Stay | 1 | 2004 | 43 | 0.060 |
Why?
|
| Placebos | 2 | 2016 | 44 | 0.060 |
Why?
|
| Uganda | 1 | 2024 | 197 | 0.050 |
Why?
|
| Bacteriological Techniques | 2 | 2015 | 54 | 0.050 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2004 | 111 | 0.050 |
Why?
|
| Family | 1 | 2023 | 35 | 0.050 |
Why?
|
| Oximetry | 1 | 2023 | 6 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Case Management | 1 | 2022 | 5 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2004 | 102 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 39 | 0.050 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 16 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 19 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2023 | 95 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 57 | 0.050 |
Why?
|
| Genes, Bacterial | 2 | 2012 | 23 | 0.050 |
Why?
|
| Research | 1 | 2022 | 65 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 101 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 23 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2016 | 656 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Malawi | 1 | 2021 | 87 | 0.050 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2021 | 4 | 0.050 |
Why?
|
| Inflammation | 1 | 2022 | 104 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 142 | 0.050 |
Why?
|
| Absorption, Physiological | 1 | 2021 | 2 | 0.050 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 3 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hepcidins | 1 | 2021 | 6 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Child Health | 1 | 2021 | 77 | 0.050 |
Why?
|
| Geography | 1 | 2021 | 60 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 33 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 34 | 0.040 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.040 |
Why?
|
| Hemagglutinins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 12 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2020 | 18 | 0.040 |
Why?
|
| Viral Fusion Proteins | 1 | 2020 | 13 | 0.040 |
Why?
|
| Haplotypes | 1 | 2021 | 125 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 31 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.040 |
Why?
|
| Nepal | 1 | 2020 | 6 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 253 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 49 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 40 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 124 | 0.040 |
Why?
|
| Virus Shedding | 2 | 2013 | 24 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 306 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 9 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 24 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 26 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 22 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Phylogeny | 2 | 2013 | 231 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 35 | 0.040 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2019 | 10 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.040 |
Why?
|
| Hypergammaglobulinemia | 1 | 2019 | 3 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2020 | 104 | 0.040 |
Why?
|
| Ureaplasma | 1 | 2019 | 4 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 2 | 0.040 |
Why?
|
| Blood Culture | 1 | 2019 | 11 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 32 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Hemagglutination | 1 | 2018 | 3 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 48 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Americas | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 56 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 127 | 0.040 |
Why?
|
| Belgium | 1 | 2018 | 6 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 56 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 72 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 385 | 0.040 |
Why?
|
| Pharynx | 1 | 2018 | 4 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 151 | 0.040 |
Why?
|
| Kinetics | 1 | 2017 | 65 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2017 | 55 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2017 | 45 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 46 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2017 | 33 | 0.030 |
Why?
|
| Immunoglobulin D | 1 | 2017 | 4 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2017 | 13 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Health Policy | 1 | 2017 | 140 | 0.030 |
Why?
|
| Live Birth | 1 | 2016 | 5 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 11 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 10 | 0.030 |
Why?
|
| Meningitis | 1 | 2016 | 26 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 2015 | 2 | 0.030 |
Why?
|
| Microbial Interactions | 1 | 2015 | 2 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2015 | 13 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 15 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 106 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 15 | 0.030 |
Why?
|
| Child Day Care Centers | 1 | 2013 | 4 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 23 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 45 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2013 | 28 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2012 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 64 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2013 | 135 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 253 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 9 | 0.020 |
Why?
|
| Oropharynx | 1 | 2011 | 17 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 217 | 0.020 |
Why?
|
| Anti-HIV Agents | 2 | 2011 | 1324 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 199 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 303 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 472 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2007 | 7 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2007 | 52 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 31 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2006 | 8 | 0.020 |
Why?
|
| Calcitonin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2005 | 28 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2006 | 22 | 0.020 |
Why?
|
| Genotype | 1 | 2007 | 442 | 0.020 |
Why?
|
| Radiography | 1 | 2006 | 80 | 0.020 |
Why?
|
| Immunity | 1 | 2005 | 10 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 20 | 0.020 |
Why?
|
| Lung | 1 | 2006 | 70 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 27 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 64 | 0.020 |
Why?
|
| African Americans | 1 | 2005 | 47 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 133 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 171 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 227 | 0.010 |
Why?
|